HelioBioSys, Inc.

HelioBioSys is a company that harnesses the unique qualities of cyanobacteria to create novel ingredients that protect and nourish the human skin. The company's family of marine cyanobacteria set a new standard for clean, natural beauty products. HelioBioSys aims to create these products in a clean, safe, effective, natural, cruelty-free, and fragrance-free way.

HelioBioSys uses a mixed population of carefully selected non-genetically modified marine cyanobacteria that obtain their energy from the sun, and carbon and nitrogen from the atmosphere. These highly efficient and robust bacteria are grown in seawater in outdoor growth systems that stimulates production of human skin care ingredients.

Harsh conditions on the early Earth leads nature’s first photosynthetic organisms to develop protection from UV rays, to shield themselves from drying out and to repair themselves. The metabolites they produce have been tested by evolution for safety and effectiveness. The company grows the cultures sustainably, extracts the materials cost-effectively, and delivers them to one's skin in safe and effective skin and sun care products. Due to the cyanobacterial compounds being used by HelioBioSys, the company's products are multi-functional. The functions are for UV-A & B protection, anti-aging, anti-inflammatory, and an emollient.

Since February 2020, HelioBioSys conducts an outdoor cultivation at the AzCATI facility in Mesa Arizona, and isolates, characterizes and purifies mycosporine-like amino acids. There is an exploration of a novel purification process that could enable an economically viable recovery process for these valuable compounds.

Since 2018, HelioBioSys conducts both indoor and outdoor cultivation and scales up separation in larger tangential flow filtration systems. The company isolates both EPS and phycocyanins from the cultures and demonstrates improved recovery, and completes a full chemical analysis of the EPS material and samples for safety and efficacy testing by an accredited outside laboratory.

Since 2016, the company simultaneously optimizes and scales up upstream and downstream processes leading to the commercialization of the production of various metabolites derived from their consortium of cyanobacteria.